Danaher Corporation and China Health Media Group File IPO Prospectus to Accelerate Biopharmaceutical Development in China

ShanghaiNovember 14, 2022PR Newswire -- November 6, 2022, at the fifth China International Import Expo, Danaher Corporation partnered with China Health Media Group to sign a strategic cooperation agreement in areas such as the application of innovative technologies in vaccine, cell therapy drugs, traditional Chinese medicine research and development, and quality control.

Danaher Corporation Partners with China Health Media Group to Accelerate the Development of China's Biopharmaceutical Industry

Ms. Wei Chunyan, Vice President of Government Affairs at Danaher China, stated: "For many years, the China Health Media Group has upheld its mission of serving drug regulation, continuously providing intellectual support for regulatory initiatives and the development of the pharmaceuticals industry. This collaboration between Danaher and the China Health Media Group brings together resources from regulators, industry, and research institutes to promote cooperation in a wide range of fields including biopharmaceuticals, vaccines, cell therapy, gene therapy, food safety, and traditional Chinese medicine research and development. It will advance the application of innovative technologies, enhance quality control standards, and build professional capacity, making it highly significant."

Chairman of China Health Media GroupWu Shaozhen spoke online: "This strategic cooperation with Danaher is another fruitful outcome of China Health Media Group's international cooperation efforts. Danaher’s achievements in life sciences and related fields are remarkable. I am very much looking forward to the research results in areas such as medical innovation technology, cell therapy business, traditional Chinese medicine R&D and quality control, as well as the compilation and translation of the book on biopharmaceuticals, which will support the dissemination and application of cutting-edge international technologies in China, and contribute to the advancement of talent cultivation and technical progress in China’s life sciences and pharmaceutical industries. I sincerely hope that both parties will continue to innovate cooperation models and improve the quality of collaboration in the future, contributing to the development of China’s biopharmaceutical industry and the building of a Healthy China."

Chairman of China Health Media Group, Wu Shaozhen

President of Danaher China Life Science Platform, Li Lei"In the past few years, our cooperation with China Health Media has been continuously reaching new levels. This strategic cooperation signing is..."Danaher Localization in China4.0 Strategy -- 'Create and Elevate China'"Another new attempt. In the past two years, we have witnessed the influence of China Health Media Group and the development of regulatory science it represents. This is closely related to the growth of Danaher's health business in China. We highly anticipate that, with the advancement of the 'Create and Elevate China' strategy, the life sciences platform will engage in more comprehensive collaborations with diverse partners across China."

President of Danaher China Life Science Platform, Li Lei

At the same time, the two parties will jointly compile and publish books such as "Biopharmaceutical Processes" to support the popularization and application of international cutting-edge technical tools in relevant fields in China, assist in the cultivation of talent in China's life sciences and pharmaceutical R&D industries, and accelerate the development of China's biopharmaceuticals industry.

Yang Hongyan, R&D Director of Cytiva ChinaSaid: "As a modern industrial system and strategic emerging industry, the biopharmaceutical industry has made significant progress over the past decade. This industry is full of opportunities but also faces considerable challenges. The content of this book covers not only R&D and the market but also various aspects such as regulations and policies. It can even be called an encyclopedia in the biopharmaceutical field. We look forward to *Biopharmaceutical Processes* empowering our industry, helping to enhance the cultivation of industry R&D talent, and achieving a win-win future."

Zhao Yanyi, General Manager of China Food and Drug Administration MagazineDelivered an online speech: "Cytiva is an outstanding global technology and service provider with a century-old history, committed to advancing unseen technologies and accelerating extraordinary therapies. Regarding the book *Biopharmaceuticals*, we have conducted a thorough evaluation and research. We believe that the compilation and publication of this book can bring international leading experiences and technologies in biopharmaceutical development, process design, and implementation to China, serving as a highly beneficial supplement and promotion for the high-quality development of China's thriving biopharmaceutical industry."